In our research, we use cohort- and registry-based information in individuals to investigate primarily metabolic- and lifestyle factors in relation to cancer risk and prognosis, with the addition of genetic information in some studies. The larger projects driven by our group are the Northern Europe-based Metabolic syndrome and Cancer project (Me-Can), and two Sweden-based projects on prostate cancer and urinary bladder cancer, respectively. Me-Can includes around 800,000 individuals and 80,000 incident cancer cases amongst whom we and Me-Can collaborators investigate relationships between metabolic factors and cancer risk. In the Swedish studies on prostate cancer and bladder cancer, we investigate metabolic factors and disease in detail by tumour characteristics and progression. Several Swedish cohorts and national registries are included in these studies.